William Blair analyst Sami Corwin has maintained their bullish stance on NGNE stock, giving a Buy rating today.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Sami Corwin’s rating is based on several strategic developments within Neurogene’s clinical pipeline. The company has successfully completed discussions with the FDA regarding its Embolden trial for NGN-401, which is a gene therapy aimed at treating Rett syndrome. This progress, coupled with the presentation of new nonclinical data, underscores Neurogene’s commitment to advancing its therapeutic offerings.
Furthermore, the expansion of the Embolden trial to 13 sites is expected to facilitate rapid enrollment and dosing, as the company has previously demonstrated efficiency in patient treatment with fewer sites. This expansion also reflects a strong interest in Neurogene’s therapy. Additionally, the trial’s design, with a 12-month endpoint, aims to support full FDA approval, potentially offering a more robust BLA package and broader label compared to competitors. These factors collectively contribute to the Buy rating, indicating confidence in Neurogene’s strategic direction and potential market impact.